Thermo Fisher Scientific Balans Gezondheid
Financiële gezondheid criteriumcontroles 3/6
Thermo Fisher Scientific heeft een totaal eigen vermogen van $49.1B en een totale schuld van $35.3B, wat de schuld-eigenvermogensverhouding op 71.9% brengt. De totale activa en totale passiva bedragen respectievelijk $100.4B en $51.3B. De EBIT Thermo Fisher Scientific is $7.4B waardoor de rentedekking 24.4 is. Het heeft contanten en kortetermijnbeleggingen van $6.6B.
Belangrijke informatie
71.9%
Verhouding schuld/eigen vermogen
US$35.31b
Schuld
| Rente dekkingsratio | 24.4x |
| Contant | US$6.65b |
| Aandelen | US$49.10b |
| Totaal verplichtingen | US$51.27b |
| Totaal activa | US$100.36b |
Recente financiële gezondheidsupdates
These 4 Measures Indicate That Thermo Fisher Scientific (NYSE:TMO) Is Using Debt Reasonably Well
Sep 21
Is Thermo Fisher Scientific (NYSE:TMO) A Risky Investment?
Jun 18We Think Thermo Fisher Scientific (NYSE:TMO) Can Stay On Top Of Its Debt
Mar 12Recent updates
Thermo Fisher Scientific: Near The Bottom And Attractively Valued
Nov 14Thermo Fisher Scientific Q3: Expecting Market Recovery In FY25; Upgrade To 'Buy'
Oct 23Thermo Fisher Scientific: Fantastic Company, Rich Valuation
Oct 04These 4 Measures Indicate That Thermo Fisher Scientific (NYSE:TMO) Is Using Debt Reasonably Well
Sep 21Thermo Fisher Scientific Inc.'s (NYSE:TMO) Price Is Out Of Tune With Earnings
Aug 16Thermo Fisher Scientific: Microscopic Signs Of Growth Emerging
Jul 25A Look At The Fair Value Of Thermo Fisher Scientific Inc. (NYSE:TMO)
Jul 11Is Thermo Fisher Scientific (NYSE:TMO) A Risky Investment?
Jun 18Low Yield, High Growth: Unveiling The Power Of Thermo Fisher's Dividends
Jun 07Thermo Fisher: Renewed Growth Yet To Materialize, But Already Priced In (Rating Downgrade)
Apr 30Thermo Fisher Scientific Inc. (NYSE:TMO) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Apr 27Why Thermo Fisher Scientific Inc. (NYSE:TMO) Could Be Worth Watching
Apr 24Thermo Fisher Scientific: Too Hot To Handle
Apr 15Investors Still Waiting For A Pull Back In Thermo Fisher Scientific Inc. (NYSE:TMO)
Apr 02We Think Thermo Fisher Scientific (NYSE:TMO) Can Stay On Top Of Its Debt
Mar 12Thermo Fisher's Bright Future Makes It A Great Buy On Weakness
Feb 06Here's What Analysts Are Forecasting For Thermo Fisher Scientific Inc. (NYSE:TMO) After Its Yearly Results
Feb 02Thermo Fisher: Blue Chip Stock Melded With Growth Characteristics
Jan 16Thermo Fisher: Downturn In Pharma And Biotech And Weak China Growth; Initiate With 'Hold'
Jan 06Is Now An Opportune Moment To Examine Thermo Fisher Scientific Inc. (NYSE:TMO)?
Dec 29Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $23.8B ) TMO } overtreffen de korte termijn passiva ( $14.6B ).
Langlopende schulden: De kortetermijnactiva van TMO ( $23.8B ) dekken de langetermijnschulden ( $36.7B ) niet.
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: De netto schuld/eigen vermogen ratio ( 58.4% ) TMO wordt als hoog beschouwd.
Schuld verminderen: De schuld/eigen vermogen-ratio van TMO is de afgelopen 5 jaar gestegen van 58.2% naar 71.9%.
Schuldendekking: De schuld van TMO wordt goed gedekt door de operationele kasstroom ( 25.8% ).
Rentedekking: De rentebetalingen op de schuld van TMO worden goed gedekt door EBIT ( 24.4 x dekking).